Tumor biology depends upon intrinsic tumor characteristics, heterotypic cell-cell interactions, and the modulation of both by environmental factors. Computational models that incorporate all of these biological determinants are needed to accurately predict tumor biology and patient prognosis. In this project, we will identify human-mouse conserved biology by integrating multiple data types coming from human tumors, human and mouse cell lines, and mouse tumor models, and then use these data to build improved outcome predictors for breast cancer patients that can be used to help make treatment decisions. We will combine high dimensional tumor genomic data (expression, copy number, and MicroRNA) with information from cell-cell interactions and stress responses for outcome predictions. The mouse tumor models provide a rich resource for the identification of important tumor biology (i.e. modules) that will increase our knowledgebase regarding carcinogenesis in both species, and these modules will be objectively tested for prognostic value in humans. We recently developed a risk of relapse predictor based upon a Cox proportional hazards model that showed good discriminatory accuracy across all breast cancer patients. A unique aspect of our model was that it combined gene expression (5 intrinsic subtypes) and clinical variables (tumor size and node status) and was accurate in predicting 7 year relapse probabilities. We will test the predictive value of new genomic modules identified in this project by adding them to this Cox model and determining if they improve outcome predictions. These new modules will be derived from an existing database of ~1000 human breast tumors with gene expression and clinical data and a complementary database of gene expression from 250 mouse mammary tumors from 23 different models. Even this large comparative resource is inadequate to identify most biologically relevant modules, and therefore, these data will be supplemented with new data on MicroRNAs, tumor DNA copy number changes, experimental data on tumor microenvironment and stress responses obtained from in vitro cell line co-cultures and whole mouse studies. An important facet of our analytic method is that it can use data from experiments performed in mice, translate these to humans, and then simultaneously utilize disparate data types (like gene expression and clinical variables) in a single evaluative framework. Emphasizing conserved features across species, the aggregation of gene-level information into modules, and the inclusion of multiple genomic data types with clinical features should provide improvements in predicting patient outcomes, and will result in advances in our understanding of breast cancer biology that may become predictive biomarkers.

Public Health Relevance

Predicting breast cancer patient outcomes remains challenging despite many advances in the postgenomic era. This project will develop an analytic framework for integrating and simultaneously evaluating genomic and clinical data types, with the ultimate goal of developing a robust computational predictor for breast cancer patient outcomes. Special emphasis will be on placed on better integrating the role of cell-cell interactions and stress responses in predicting the clinical course of disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA138255-05
Application #
8307405
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O3))
Program Officer
Verma, Mukesh
Project Start
2008-09-19
Project End
2013-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$455,204
Indirect Cost
$146,729
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Pfefferle, Adam D; Spike, Benjamin T; Wahl, Geoff M et al. (2015) Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. Breast Cancer Res Treat 149:425-37
Casbas-Hernandez, Patricia; Sun, Xuezheng; Roman-Perez, Erick et al. (2015) Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev 24:406-14
Rotunno, Melissa; Sun, Xuezheng; Figueroa, Jonine et al. (2014) Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. Breast Cancer Res 16:R74
Sun, Xuezheng; Sandhu, Rupninder; Figueroa, Jonine D et al. (2014) Benign breast tissue composition in breast cancer patients: association with risk factors, clinical variables, and gene expression. Cancer Epidemiol Biomarkers Prev 23:2810-8
Harrell, J Chuck; Pfefferle, Adam D; Zalles, Nicole et al. (2014) Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis 31:33-45
Iglesia, Michael D; Vincent, Benjamin G; Parker, Joel S et al. (2014) Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20:3818-29
Oh, Daniel S; Cheang, Maggie C U; Fan, Cheng et al. (2014) Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiat Res 181:193-207
Sundaram, Sneha; Freemerman, Alex J; Galanko, Joseph A et al. (2014) Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice. PLoS One 9:e111394
Prat, A; Lluch, A; Albanell, J et al. (2014) Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 111:1532-41
Usary, Jerry; Zhao, Wei; Darr, David et al. (2013) Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 19:4889-99

Showing the most recent 10 out of 50 publications